ACHV
Achieve Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$8.49
+2.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 111.0K | 228.0K | 229.0K | — | — |
| Gross Profit | (111.0K) | (228.0K) | (229.0K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 16.3M | 23.0M | 22.8M | 15.8M | 30.1M |
| SG&A Expense | 41.9M | 31.9M | 16.3M | 11.4M | 10.7M |
| General & Admin Expense | 41.9M | 31.9M | 16.3M | 11.4M | 10.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 48.0K | (229.0K) | — | — |
| Total Operating Expenses | 58.2M | 54.7M | 38.8M | 27.3M | 40.8M |
| Cost and Expenses | 58.3M | 54.9M | 39.1M | 27.3M | 40.8M |
| Operating Income (EBIT) | (58.3M) | (54.9M) | (39.1M) | (27.3M) | (40.8M) |
| Non-Operating | |||||
| Interest Income | 2.8M | 1.5M | 2.4M | 825.0K | 199.0K |
| Interest Expense | 994.0K | 819.0K | 2.2M | 2.9M | 1.8M |
| Net Interest Income | 1.8M | 676.0K | 176.0K | (2.0M) | (1.6M) |
| Other Non-Op Income/Expense | (55.8M) | 232.0K | (758.0K) | (2.6M) | (1.6M) |
| Non-Operating Income (excl Interest) | 54.8M | (1.1M) | (1.4M) | (288.0K) | (239.0K) |
| EBT (Pre-Tax Income) | (114.0M) | (54.6M) | (39.8M) | (29.8M) | (42.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (114.0M) | (54.6M) | (39.8M) | (29.8M) | (42.4M) |
| Earnings from Cont. Ops | (114.0M) | (54.6M) | (39.8M) | (29.8M) | (42.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (114.0M) | (54.6M) | (39.8M) | (29.8M) | (42.4M) |
| Per Share | |||||
| Basic EPS | ($1.55) | ($1.25) | ($1.24) | ($1.50) | ($3.95) |
| Diluted EPS | ($1.55) | ($1.25) | ($1.24) | ($1.50) | ($3.95) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 93.5M | 43.6M | 32.1M | 19.8M | 10.6M |
| Diluted Shares Outstanding | 93.5M | 43.6M | 32.1M | 19.8M | 10.6M |
| Profitability Metrics | |||||
| EBITDA | (112.8M) | (53.6M) | (37.4M) | (26.7M) | (40.3M) |
| D&A | 227.0K | 228.0K | 229.0K | 228.0K | 236.0K |
| EBIT | (113.0M) | (53.8M) | (37.6M) | (27.0M) | (40.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026